Skip to main content

SL-401

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • RegistryNCT03113643
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia
  • SponsorDana-Farber Cancer Institute
How SL-401 worksNCT031136431 min

What the film says

Read the transcript

Older adults with acute myeloid leukemia often get two drugs, azacitidine and venetoclax. Remissions come, but many fade, especially with a TP53 mutation.

The idea: add a third drug that carries a bacterial toxin straight into leukemia cells.

Tagraxofusp is interleukin-3, a growth signal these cells crave, fused to diphtheria toxin. Cells carrying the CD123 receptor pull it in and die. It is already approved for a rare leukemia. In the lab, azacitidine re-sensitized resistant cells and left them leaning on BCL-2, venetoclax's target.

In fifty-six adults, the triplet was tolerable; in untreated high-risk AML, sixty-nine percent responded, including half of those with TP53 mutations.

Andrew Lane leads it at Dana-Farber, with City of Hope and MD Anderson. Public record; not medical advice.

Sources behind this film

  • PaperPhase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

    Lane AA. Blood Adv, 2024

    Azacitidine + venetoclax standard for older AML; remissions fade, TP53 worst; Tagraxofusp = IL-3 fused to truncated diphtheria toxin; CD123 target; approved for BPDCN; Azacitidine re-sensitizes resistant cells; increased dependence on BCL-2 (venetoclax target); 56 adults; tolerable; 69% response in untreated adverse-risk AML; 7/13 (54%) with TP53 mutations

  • ClinicalTrials.gov record NCT03113643

    Azacitidine + venetoclax standard for older AML; remissions fade, TP53 worst; Tagraxofusp = IL-3 fused to truncated diphtheria toxin; CD123 target; approved for BPDCN; Andrew Lane, Dana-Farber; City of Hope, MD Anderson

The drug

What is being tested.

SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.

Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.

This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has approved azacitidine and venetoclax as a treatment option for AML.

The study

How the trial runs.

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed diagnosis of acute myeloid leukemia (AML) [Cohort B] or myelodysplastic syndrome (MDS) [Cohort A] or BPDCN [Cohort C] per 2016 WHO criteria
  • CD123 / IL3RA expression on the subject's AML or MDS blasts or BPDCN cells determined locally within 3 months of first protocol treatment
  • Age >= 18 years with relapsed or refractory AML (hydroxyurea is not considered a prior treatment regimen) [Cohort B]
  • Age >= 18 years with treatment-naïve AML who decline intensive induction chemotherapy or who are unfit due to co-morbidity or other factors (see APPENDIX A for unfitness definitions) (hydroxyurea is not considered a prior treatment regimen) [Cohort B]
  • Age >= 18 years with MDS and > 10% myeloblasts in the bone marrow [Cohort A]
  • Age >= 18 years with relapsed or refractory BPDCN (hydroxyurea is not considered a prior treatment regimen) [Cohort C]

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.